<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Clinical manifestations, evaluation, and staging of renal cell carcinoma</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Clinical manifestations, evaluation, and staging of renal cell carcinoma</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Clinical manifestations, evaluation, and staging of renal cell carcinoma</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Michael B Atkins, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jerome P Richie, MD, FACS</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sonali M Shah, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Dec 15, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Malignant neoplasms involving the kidney may be primary or secondary tumors. Secondary renal neoplasms are usually clinically insignificant and discovered at postmortem examination.</p><p>Renal cell carcinomas (RCCs), which originate within the renal cortex, constitute 80 to 85 percent of primary renal neoplasms. Transitional cell carcinomas of the renal pelvis are the next most common (approximately 8 percent). Other parenchymal epithelial tumors, such as oncocytomas, collecting duct tumors, and renal sarcomas, are rare. Nephroblastoma or Wilms tumor is common in children (5 to 6 percent of all primary renal tumors). (See  <a class="medical medical_review" href="/z/d/html/2982.html" rel="external">"Epidemiology, pathology, and pathogenesis of renal cell carcinoma"</a> and  <a class="medical medical_review" href="/z/d/html/2987.html" rel="external">"Malignancies of the renal pelvis and ureter"</a>.)</p><p>The clinical and radiographic presentation of RCC and the methods used for tumor staging, as well as their potential application for screening, will be reviewed here. The prognosis and treatment of RCC are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/2961.html" rel="external">"Prognostic factors in patients with renal cell carcinoma"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">CLINICAL MANIFESTATIONS</span><span class="headingEndMark"> — </span>Patients with RCC can present with a range of symptoms; unfortunately, many patients are asymptomatic until the disease is advanced. At presentation, approximately 25 percent of individuals either have distant metastases or advanced locoregional disease [<a href="#rid1">1</a>].</p><p>Patients with localized disease can present with a wide array of symptoms and/or laboratory abnormalities, or they may be diagnosed incidentally. In one review of 309 consecutive patients with RCC, the most common presenting symptoms were hematuria, abdominal mass, pain, and weight loss [<a href="#rid2">2</a>]. In contemporary series, fewer patients have the typical symptoms and there is an increased frequency of incidental diagnosis due to radiologic procedures performed for other indications [<a href="#rid3">3</a>]. (See  <a class="medical medical_review" href="/z/d/html/2982.html" rel="external">"Epidemiology, pathology, and pathogenesis of renal cell carcinoma", section on 'Epidemiology'</a> and  <a class="medical medical_review" href="/z/d/html/2970.html" rel="external">"Diagnostic approach, differential diagnosis, and management of a small renal mass"</a>.)</p><p>This shift in pattern of presentation along with improvements in therapy have contributed to better outcomes in RCC. In a series of 701 patients, those who were diagnosed incidentally had a significantly better disease-specific survival at five years (76 versus 44 percent in those with symptoms) [<a href="#rid4">4</a>]. Multivariate analysis showed that the difference was due to the lower stage and histologic grade at the time of diagnosis. (See  <a class="medical medical_review" href="/z/d/html/2984.html" rel="external">"Systemic therapy of advanced clear cell renal carcinoma"</a>.)</p><p class="headingAnchor" id="H3"><span class="h2">Symptoms and signs</span><span class="headingEndMark"> — </span>For patients not diagnosed incidentally, symptoms and signs are generally related to invasion of adjacent structures or distant metastases.</p><p class="bulletIndent1"><span class="glyph">●</span>The classic triad of RCC (flank pain, hematuria, and a palpable abdominal renal mass) occurs in at most 9 percent of patients; when present, it strongly suggests locally advanced disease [<a href="#rid2">2,5</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hematuria is observed only with tumor invasion of the collecting system. In an early series, hematuria was observed in almost 40 percent of patients [<a href="#rid6">6</a>]. When severe, the bleeding can cause clots and "colicky" discomfort. Clot formation does not occur with glomerular bleeding; thus, the presence of clots is a significant finding in patients with otherwise unexplained hematuria. (See  <a class="medical medical_review" href="/z/d/html/7208.html" rel="external">"Etiology and evaluation of hematuria in adults", section on 'Blood clots'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>An abdominal or flank mass, which is associated with lower pole tumors, is more commonly palpated in the thin adult. The mass is generally firm, homogeneous, nontender, and moves with respiration.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Scrotal varicoceles, the majority of which are left sided, are observed in as many as 11 percent of males with RCC [<a href="#rid7">7</a>]. Varicoceles typically fail to empty when the patient is recumbent. This finding should always arouse suspicion for a kidney tumor that has obstructed the gonadal vein where it enters the renal vein.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Inferior vena cava involvement can produce a variety of clinical manifestations, including lower extremity edema, ascites, hepatic dysfunction (possibly related to a Budd-Chiari syndrome), and pulmonary emboli.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Among patients with disseminated disease, signs or symptoms may be due to metastatic tumor; the most common sites of involvement include the lungs, lymph nodes, bone, liver, and brain. In this setting, the diagnosis is often made by biopsy of an accessible metastasis in the setting of a renal mass on abdominal computed tomography (CT). (See  <a class="medical medical_review" href="/z/d/html/2969.html" rel="external">"Surveillance for metastatic disease after definitive treatment for renal cell carcinoma", section on 'Sites of metastasis'</a>.)</p><p></p><p class="headingAnchor" id="H4"><span class="h2">Paraneoplastic symptoms</span><span class="headingEndMark"> — </span>Patients with RCC can present with or subsequently develop systemic symptoms or paraneoplastic syndromes [<a href="#rid8">8-10</a>]. In some instances, these may be due to ectopic production of various hormones (eg, erythropoietin, parathyroid hormone-related protein [PTHrP], gonadotropins, human chorionic somatomammotropin, an adrenocorticotropic hormone [ACTH]-like substance, renin, glucagon, insulin) [<a href="#rid10">10</a>].</p><p class="headingAnchor" id="H5"><span class="h3">Anemia</span><span class="headingEndMark"> — </span>Anemia, which can precede the diagnosis of RCC by several months, has been reported in 29 to 88 percent of patients with advanced disease [<a href="#rid7">7,10-12</a>]. The anemia is often disproportionately severe, can be either normocytic or microcytic, and is frequently associated with iron studies typical of those observed with the anemia of chronic disease. (See  <a class="medical medical_review" href="/z/d/html/7149.html" rel="external">"Anemia of chronic disease/anemia of inflammation"</a>.)</p><p class="headingAnchor" id="H6"><span class="h3">Hepatic dysfunction</span><span class="headingEndMark"> — </span>Hepatic dysfunction is an uncommon occurrence in patients with RCC, which is called Stauffer syndrome when it occurs in the absence of liver metastases [<a href="#rid13">13-15</a>]. In a series of 365 patients, 21 percent had a paraneoplastic elevation in serum alkaline phosphatase [<a href="#rid15">15</a>].</p><p>When hepatic dysfunction is present, it frequently is associated with fever, weight loss, fatigue, and a poor prognosis [<a href="#rid16">16</a>]. The dysfunction may result from tumor production of cytokines, such as granulocyte-macrophage colony-stimulating factor (GM-CSF) and possibly interleukin 6 (IL-6) [<a href="#rid17">17-19</a>].</p><p>Nephrectomy may result in the amelioration of hepatic dysfunction [<a href="#rid13">13,14</a>]. Recurrent elevations of liver enzymes in such patients may herald local recurrence or distant metastatic disease [<a href="#rid15">15</a>].</p><p class="headingAnchor" id="H7"><span class="h3">Fever</span><span class="headingEndMark"> — </span>Fever, which occurs in up to 20 percent of patients, is usually intermittent and is frequently accompanied by night sweats, anorexia, weight loss, and fatigue [<a href="#rid10">10,20</a>]. Its origin is unclear [<a href="#rid10">10</a>].</p><p class="headingAnchor" id="H8"><span class="h3">Hypercalcemia</span><span class="headingEndMark"> — </span>Hypercalcemia occurs in up to 15 percent of patients with advanced RCC and can result from a number of different mechanisms:</p><p class="bulletIndent1"><span class="glyph">●</span>Lytic bone metastases.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Overproduction of PTHrP [<a href="#rid21">21-24</a>]. Concurrent production of IL-6 may enhance the action of PTHrP [<a href="#rid25">25,26</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Increased production of prostaglandins that promote bone resorption [<a href="#rid27">27,28</a>]. In such patients, the hypercalcemia can respond to administration of a nonsteroidal anti-inflammatory drug (NSAID), such as <a class="drug drug_general" data-topicid="8559" href="/z/d/drug information/8559.html" rel="external">indomethacin</a> [<a href="#rid27">27</a>].</p><p></p><p>The pathogenesis and management of hypercalcemia in patients with malignancy are discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/842.html" rel="external">"Hypercalcemia of malignancy: Mechanisms"</a> and  <a class="medical medical_review" href="/z/d/html/850.html" rel="external">"Treatment of hypercalcemia"</a> and  <a class="medical medical_review" href="/z/d/html/2801.html" rel="external">"Osteoclast inhibitors for patients with bone metastases from breast, prostate, and other solid tumors"</a>.)</p><p class="headingAnchor" id="H9"><span class="h3">Cachexia</span><span class="headingEndMark"> — </span>As with other tumors, patients with RCC may suffer from significant cachexia [<a href="#rid10">10</a>]. (See  <a class="medical medical_review" href="/z/d/html/2817.html" rel="external">"Pathogenesis, clinical features, and assessment of cancer cachexia"</a>.)</p><p class="headingAnchor" id="H10"><span class="h3">Erythrocytosis</span><span class="headingEndMark"> — </span>Erythrocytosis occurs in 1 to 5 percent of patients with advanced RCC and appears to be due to constitutive production of erythropoietin [<a href="#rid29">29</a>]. In addition, since the mutated von Hippel-Lindau protein is associated with impaired regulation of hypoxia-induced proteins [<a href="#rid30">30,31</a>], erythrocytosis may be directly related to impaired degradation of hypoxia-inducible transcription factors under normoxic conditions. (See  <a class="medical medical_review" href="/z/d/html/7161.html" rel="external">"Regulation of erythropoiesis"</a> and  <a class="medical medical_review" href="/z/d/html/2982.html" rel="external">"Epidemiology, pathology, and pathogenesis of renal cell carcinoma"</a>.)</p><p class="headingAnchor" id="H11"><span class="h3">Secondary (AA) amyloidosis</span><span class="headingEndMark"> — </span>Secondary (AA) amyloidosis is found in up to 5 percent of patients [<a href="#rid32">32,33</a>]. This finding reflects a chronic inflammatory response as the amyloid fibrils are composed of fragments of the acute phase reactant serum amyloid A protein. (See  <a class="medical medical_review" href="/z/d/html/5619.html" rel="external">"Pathogenesis of AA amyloidosis"</a>.)</p><p class="headingAnchor" id="H12"><span class="h3">Thrombocytosis</span><span class="headingEndMark"> — </span>Thrombocytosis is rare in patients with RCC, but its presence is associated with a poor prognosis [<a href="#rid34">34,35</a>]. The underlying mechanism is not firmly established but could be related to IL-6 production by the tumor.</p><p class="headingAnchor" id="H13"><span class="h3">Polymyalgia rheumatica</span><span class="headingEndMark"> — </span>A syndrome resembling polymyalgia rheumatica has been reported with RCC [<a href="#rid36">36</a>]. In contrast to idiopathic disease, the symptoms do not respond to <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> but are often corrected by nephrectomy. (See  <a class="medical medical_review" href="/z/d/html/8235.html" rel="external">"Clinical manifestations and diagnosis of polymyalgia rheumatica"</a>.)</p><p class="headingAnchor" id="H14"><span class="h1">DIAGNOSTIC EVALUATION</span><span class="headingEndMark"> — </span>Patients with unexplained hematuria or other symptoms, signs, or findings suggestive of possible RCC must undergo imaging evaluation for the presence of a renal mass. In addition, incidental diagnosis of RCC is becoming more common due to the frequent use of abdominal computed tomography (CT) and/or ultrasonography for evaluation of an unrelated problem. (See  <a class="medical medical_review" href="/z/d/html/7208.html" rel="external">"Etiology and evaluation of hematuria in adults"</a> and  <a class="medical medical_review" href="/z/d/html/2970.html" rel="external">"Diagnostic approach, differential diagnosis, and management of a small renal mass"</a>.)</p><p class="headingAnchor" id="H15"><span class="h2">CT or ultrasonography</span><span class="headingEndMark"> — </span>The usual first test is abdominal computed tomography (CT)  (<a class="graphic graphic_diagnosticimage graphicRef60352" href="/z/d/graphic/60352.html" rel="external">image 1</a>) or, occasionally, abdominal ultrasound.</p><p>Although ultrasonography is less sensitive than CT in detecting a renal mass, it is useful to distinguish a simple benign cyst from a more complex cyst or a solid tumor. The issues surrounding the evaluation of an asymptomatic renal mass or a cyst are discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/1681.html" rel="external">"Simple and complex kidney cysts in adults"</a> and  <a class="medical medical_review" href="/z/d/html/2970.html" rel="external">"Diagnostic approach, differential diagnosis, and management of a small renal mass"</a>.)</p><p>Summarized briefly, there are three major criteria that allow a simple cyst to be differentiated from a tumor or abscess on ultrasonography  (<a class="graphic graphic_table graphicRef67087" href="/z/d/graphic/67087.html" rel="external">table 1</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>The cyst is round and sharply demarcated with smooth walls</p><p class="bulletIndent1"><span class="glyph">●</span>There are no echoes within the cyst ("anechoic")</p><p class="bulletIndent1"><span class="glyph">●</span>There is a strong posterior wall echo, indicating good transmission through a cyst</p><p></p><p>If all of these criteria are fulfilled, no further evaluation is necessary since the likelihood of a malignancy is extremely small. If the criteria for a simple cyst by ultrasonography are not satisfied, the patient should undergo CT before and after injection of iodinated contrast. On CT, a simple cyst has a smooth appearance without a clearly delineated wall, has no enhancement with intravascular contrast, and is the density of water. CT urography allows imaging of both the renal parenchyma and the collecting system.</p><p>By comparison, thickened irregular walls or septa  (<a class="graphic graphic_diagnosticimage graphicRef77721" href="/z/d/graphic/77721.html" rel="external">image 2</a>) and enhancement after contrast injection are suggestive of malignancy  (<a class="graphic graphic_table graphicRef67087" href="/z/d/graphic/67087.html" rel="external">table 1</a>). (See  <a class="medical medical_review" href="/z/d/html/1681.html" rel="external">"Simple and complex kidney cysts in adults", section on 'Bosniak classification of kidney cysts'</a>.)</p><p class="headingAnchor" id="H16"><span class="h2">MRI</span><span class="headingEndMark"> — </span>Magnetic resonance imaging (MRI) may be useful when ultrasonography and/or CT are inconclusive or if iodinated contrast cannot be administered because of allergy or poor renal function  (<a class="graphic graphic_diagnosticimage graphicRef73120 graphicRef51129" href="/z/d/graphic/73120.html" rel="external">image 3A-B</a>). MRI is particularly helpful in cases where a neoplasm is diagnosed as it evaluates for tumor growth into the collecting system or the vessels better than the other modalities. (See  <a class="medical medical_review" href="/z/d/html/1681.html" rel="external">"Simple and complex kidney cysts in adults", section on 'Category IIF'</a> and  <a class="medical medical_review" href="/z/d/html/2985.html" rel="external">"Definitive surgical management of renal cell carcinoma"</a>.)</p><p>MRI with dynamic gadolinium contrast may be useful in distinguishing papillary or clear cell RCC from other benign and malignant solid renal neoplasms, although the examination does not obviate the need for tissue for diagnosis. In a meta-analysis, contrast enhancement in the corticomedullary phase on MRI diagnosed papillary RCC with a pooled sensitivity of 86 percent (95% CI 68-94 percent) and specificity of 92 percent (95% CI 76-98 percent) [<a href="#rid37">37</a>]. In one large series, clear cell carcinoma was diagnosed with a sensitivity of 85 percent and specificity of 76 percent [<a href="#rid38">38</a>].</p><p class="headingAnchor" id="H1220636680"><span class="h2">Angiography</span><span class="headingEndMark"> — </span>Catheter-based renal angiography is rarely necessary. If preoperative mapping of the vasculature is required prior to possible nephron-sparing surgery, either CT or MR angiography is preferable.</p><p class="headingAnchor" id="H17"><span class="h1">TISSUE DIAGNOSIS</span><span class="headingEndMark"> — </span>For patients with localized disease, nephrectomy or partial nephrectomy is used in most cases to obtain tissue for diagnosis of RCC. For patients presenting with metastatic disease who plan to omit or defer cytoreductive nephrectomy, establishing diagnosis via a biopsy of a metastasis is preferred. After the presumptive diagnosis has been made based upon imaging studies, the patient must be evaluated for the extent of local involvement and the presence of metastatic disease prior to surgery. (See <a class="local">'Staging studies'</a> below.)</p><p>In addition to establishing the diagnosis of malignancy, tissue diagnosis provides information about the histopathologic type of RCC, which may have important implications for prognosis and treatment. (See  <a class="medical medical_review" href="/z/d/html/2982.html" rel="external">"Epidemiology, pathology, and pathogenesis of renal cell carcinoma", section on 'Pathology'</a>.)</p><p>The role of percutaneous biopsy is more limited, although it may be used for a small renal mass if there is a high index of suspicion for a metastatic lesion to the kidney, lymphoma, or a focal kidney infection. A biopsy can also be used to confirm a diagnosis of RCC in patients who are not surgical candidates, although biopsy of a metastatic lesion, if present, is often preferable. (See  <a class="medical medical_review" href="/z/d/html/2970.html" rel="external">"Diagnostic approach, differential diagnosis, and management of a small renal mass"</a>.)</p><p class="headingAnchor" id="H18"><span class="h1">STAGING STUDIES</span></p><p class="headingAnchor" id="H2856293746"><span class="h2">Abdominal CT</span><span class="headingEndMark"> — </span>The extent of local and regional involvement is determined primarily by abdominal computed tomography (CT), which is extremely accurate in staging RCC. In a retrospective study of 100 RCCs, for example, preoperative CTs were compared with the findings obtained at surgery [<a href="#rid39">39</a>]. The following results were obtained:</p><p class="bulletIndent1"><span class="glyph">●</span>For the detection of renal vein invasion, CT was 78 percent sensitive and 96 percent specific.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For the detection of metastatic adenopathy, CT was 83 percent sensitive and 88 percent specific.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For the detection of perinephric invasion, CT was only 46 percent sensitive but was 98 percent specific.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For the detection of adjacent organ invasion, CT was 100 percent specific.</p><p></p><p>The sensitivity and specificity of CT for detecting nodal metastasis depend upon the size criterion used to define suspicious nodes. At least some data suggest that approximately 50 percent of patients with radiographically enlarged nodes in the 1 to 2 cm size range do not harbor metastases [<a href="#rid40">40</a>].</p><p>The limitations of imaging for the detection of renal vein or perinephric invasion may result in upstaging in patients who undergo nephrectomy. In a series of 1448 patients with clinical T1 lesions, 134 (9 percent) were upstaged to pathologic T3a disease [<a href="#rid41">41</a>]. Patients with pathologic T3a disease had a worse three-year recurrence-free survival compared with those with pathologic T1 disease (76 versus 93 percent).</p><p class="headingAnchor" id="H2823229757"><span class="h2">Other imaging studies</span><span class="headingEndMark"> — </span>Other imaging studies that may be useful for assessing for distant metastases include bone scan, CT of the chest, magnetic resonance imaging (MRI), and positron emission tomography (PET)/CT:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Bone scan</strong> – Bone scan is indicated only in patients with bone pain and/or an elevated serum alkaline phosphatase. In one series, for example, less than 5 percent of such patients had occult bone metastases [<a href="#rid42">42</a>]. Bone scan can be falsely negative since bone metastases are frequently osteolytic rather than osteoblastic.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Chest CT or radiograph</strong> – CT of the chest is useful to evaluate for evidence of pulmonary or mediastinal lymph node metastases. Alternatively, patients with a small renal mass may be offered a chest radiograph. (See  <a class="medical medical_review" href="/z/d/html/2970.html" rel="external">"Diagnostic approach, differential diagnosis, and management of a small renal mass", section on 'Definition'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>MRI</strong> – MRI scanning with gadolinium is superior to CT for evaluation of the inferior vena cava and right atrium when tumor involvement is suspected [<a href="#rid43">43</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>PET/CT</strong> – PET scanning has high sensitivity and specificity for the primary lesion. Although PET/CT may be more sensitive than radionuclide scanning for the detection of bone metastases, it is expensive and has limited use for routine staging [<a href="#rid44">44-46</a>].</p><p></p><p class="headingAnchor" id="H2651160064"><span class="h2">Pathology</span></p><p class="headingAnchor" id="H2896998632"><span class="h3">Isolated renal mass</span><span class="headingEndMark"> — </span>For patients with isolated solid renal masses, resection with either a partial or complete nephrectomy is preferred over biopsy because it provides the diagnosis, pathologic tumor (T) and nodal (N) staging  (<a class="graphic graphic_table graphicRef110735" href="/z/d/graphic/110735.html" rel="external">table 2</a>), and definitive treatment. Preoperative needle biopsies are usually not used for resectable renal lesions because of their low specificity [<a href="#rid47">47</a>] and concerns about tumor seeding of the peritoneum.</p><p>Although solid renal masses less than 3 cm were once thought to represent benign adenomas, distinctions based upon size are no longer used, since even small tumors frequently represent carcinomas that will grow over time [<a href="#rid48">48</a>]. Most solid renal masses require a histologic diagnosis; in patients with significant comorbidities, "watchful waiting" might be appropriate. (See  <a class="medical medical_review" href="/z/d/html/2970.html" rel="external">"Diagnostic approach, differential diagnosis, and management of a small renal mass"</a> and  <a class="medical medical_review" href="/z/d/html/1681.html" rel="external">"Simple and complex kidney cysts in adults"</a>.)</p><p class="headingAnchor" id="H1846587104"><span class="h3">Metastatic disease</span><span class="headingEndMark"> — </span>When metastatic disease is suspected at initial presentation, pathologic confirmation is required prior to starting therapy. Biopsy of a metastatic site is often easier and more informative than biopsy of the primary tumor.</p><p>In patients with a previously diagnosed nonrenal malignancy, metastatic disease is more likely than a new primary RCC. If the renal mass is nonenhancing and there is clinical evidence of progression of the nonrenal malignancy, biopsy confirmation may be unnecessary [<a href="#rid49">49</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Is there a</strong> <strong>role for upfront cytoreductive nephrectomy in staging?</strong> – The role of upfront cytoreductive nephrectomy is evolving in the era of effective treatments such as checkpoint inhibitor immunotherapy and antiangiogenic agents for patients with metastatic RCC  (<a class="graphic graphic_algorithm graphicRef109427" href="/z/d/graphic/109427.html" rel="external">algorithm 1</a>).</p><p></p><p class="bulletIndent1">In general, initial cytoreductive nephrectomy may be indicated in select patients with International Metastatic Renal Cell Carcinoma Database Consortium (IMDC)-favorable or low-intermediate risk features (ie, no or one risk factor)  (<a class="graphic graphic_table graphicRef116130" href="/z/d/graphic/116130.html" rel="external">table 3</a>). Palliative cytoreductive nephrectomy may also be indicated in those experiencing symptoms from the primary tumor (eg, pain, intractable hematuria). Further details on the approach to cytoreductive nephrectomy and supporting randomized trial data in patients with metastatic clear cell RCC are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/2963.html" rel="external">"Role of surgery in patients with metastatic renal cell carcinoma", section on 'Cytoreductive nephrectomy'</a> and  <a class="medical medical_review" href="/z/d/html/2963.html" rel="external">"Role of surgery in patients with metastatic renal cell carcinoma", section on 'Palliative nephrectomy'</a>.)</p><p></p><p class="bulletIndent1">For those with IMDC-high-intermediate or poor risk features (≥2 risk factors)  (<a class="graphic graphic_table graphicRef116130" href="/z/d/graphic/116130.html" rel="external">table 3</a>), initial systemic therapy is indicated, and a decision about cytoreductive nephrectomy should be delayed until more information about disease responsiveness and treatment tolerability is available. (See  <a class="medical medical_review" href="/z/d/html/2984.html" rel="external">"Systemic therapy of advanced clear cell renal carcinoma"</a> and  <a class="medical medical_review" href="/z/d/html/2962.html" rel="external">"Antiangiogenic and molecularly targeted therapy for advanced or metastatic clear cell renal carcinoma"</a>.)</p><p></p><p class="headingAnchor" id="H19"><span class="h1">TNM STAGING SYSTEM</span><span class="headingEndMark"> — </span>The eighth (2017) Tumor, Node, Metastasis (TNM) staging system is used for staging all histologic variants of RCC. This system is supported by both the American Joint Committee on Cancer (AJCC) and the International Union for Cancer Control (UICC) [<a href="#rid50">50</a>]. These TNM criteria use the anatomic extent of disease to define prognostic stage groups. (See  <a class="medical medical_review" href="/z/d/html/2961.html" rel="external">"Prognostic factors in patients with renal cell carcinoma"</a>.)</p><p>The TNM system is shown in the table  (<a class="graphic graphic_table graphicRef110735" href="/z/d/graphic/110735.html" rel="external">table 2</a>). In this system, tumors limited to the kidney are classified as T1 or T2 based upon size. T3 tumors extend into the renal vein or perinephric tissues but not beyond the Gerota fascia, while T4 tumors extend beyond the Gerota fascia, including direct extension into the ipsilateral adrenal gland. Nodal and distant metastases are simply classified as absent or present.</p><p class="headingAnchor" id="H20"><span class="h1">SOLID RENAL MASSES</span><span class="headingEndMark"> — </span>The optimal management of solid renal parenchymal masses is incompletely understood and relies upon both the ability of imaging studies to identify simple renal cysts and the likelihood of the lesion to exhibit clinically malignant behavior. The evaluation and initial management of a patient with a solid renal mass are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/2970.html" rel="external">"Diagnostic approach, differential diagnosis, and management of a small renal mass"</a>.)</p><p class="headingAnchor" id="H21"><span class="h1">SCREENING</span><span class="headingEndMark"> — </span>Screening of asymptomatic individuals is not recommended because of the low prevalence of RCC in the general population. However, individuals at high risk for the development of RCC should undergo periodic monitoring with abdominal ultrasonography, computed tomography (CT), or magnetic resonance imaging (MRI) to detect early disease [<a href="#rid51">51</a>].</p><p>Candidates for screening include patients with any of the following conditions:</p><p class="bulletIndent1"><span class="glyph">●</span>Inherited conditions associated with an increased incidence of RCC or other renal tumors, including Von Hippel-Lindau syndrome and tuberous sclerosis. (See  <a class="medical medical_review" href="/z/d/html/5193.html" rel="external">"Clinical features, diagnosis, and management of von Hippel-Lindau disease"</a> and  <a class="medical medical_review" href="/z/d/html/1684.html" rel="external">"Renal manifestations of tuberous sclerosis complex"</a> and  <a class="medical medical_review" href="/z/d/html/6175.html" rel="external">"Tuberous sclerosis complex: Clinical features"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>End-stage kidney disease, especially younger subjects without serious comorbid diseases who have been on dialysis for three to five years or more.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A strong family history of RCC. (See  <a class="medical medical_review" href="/z/d/html/2948.html" rel="external">"Hereditary kidney cancer syndromes"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Prior kidney irradiation.</p><p></p><p class="headingAnchor" id="H2805567870"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/119821.html" rel="external">"Society guideline links: Cancer of the kidney and ureters"</a>.)</p><p class="headingAnchor" id="H22"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topic (see  <a class="medical medical_patient" href="/z/d/html/888.html" rel="external">"Patient education: Renal cell carcinoma (kidney cancer) (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H23"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical manifestations</strong> – Patients with renal cell carcinoma (RCC) can present with a range of symptoms due to the tumor itself (eg, mass, pain), invasion of the urinary tract (eg, hematuria), paraneoplastic syndromes, or the presence of metastases. In addition, RCC is more frequently being diagnosed incidentally as a consequence of increased use of imaging procedures for other reasons. (See <a class="local">'Clinical manifestations'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnostic evaluation</strong> – Patients with symptoms, signs, or other findings suggestive of RCC should undergo evaluation for the presence of a renal mass. Abdominal computed tomography (CT) or ultrasound can confirm the presence of a mass, distinguish RCC from a benign cyst, and assess the extent of disease. (See <a class="local">'Diagnostic evaluation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Approach to a solitary small renal mass</strong> – In the setting of a solitary small renal mass, imaging studies <strong>cannot</strong> reliably distinguish a benign renal tumor from RCC. Thus, it is generally recommended that lesions other than simple cysts be resected. (See  <a class="medical medical_review" href="/z/d/html/2970.html" rel="external">"Diagnostic approach, differential diagnosis, and management of a small renal mass"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Staging</strong> – The tumor, node, metastasis (TNM) staging system, which is based upon the extent of the primary tumor and the presence or absence of regional lymph node involvement or distant metastases, is used for staging all histologic variants of RCC  (<a class="graphic graphic_table graphicRef110735" href="/z/d/graphic/110735.html" rel="external">table 2</a>). This staging system correlates with prognosis and provides important information for patient management. (See <a class="local">'TNM staging system'</a> above and <a class="local">'Tissue diagnosis'</a> above and <a class="local">'Staging studies'</a> above and  <a class="medical medical_review" href="/z/d/html/2961.html" rel="external">"Prognostic factors in patients with renal cell carcinoma"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Screening for individuals at high risk for RCC</strong> – Individuals thought to be at increased risk for the development of RCC should undergo routine screening with abdominal ultrasound, CT, or magnetic resonance imaging (MRI). (See <a class="local">'Screening'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li class="breakAll">Garnick MB. Primary neoplasms of the kidney. In: Therapy in Nephrology and Hypertension: A Companion to Brenner and Rector's the Kidney, Brady HR, Wilcox CS (Eds), WB Saunders, Philadelphia 1998.</li><li><a class="nounderline abstract_t">Skinner DG, Colvin RB, Vermillion CD, et al. Diagnosis and management of renal cell carcinoma. A clinical and pathologic study of 309 cases. Cancer 1971; 28:1165.</a></li><li><a class="nounderline abstract_t">Mazziotti S, Cicero G, D'Angelo T, et al. Imaging and Management of Incidental Renal Lesions. Biomed Res Int 2017; 2017:1854027.</a></li><li><a class="nounderline abstract_t">Gudbjartsson T, Thoroddsen A, Petursdottir V, et al. Effect of incidental detection for survival of patients with renal cell carcinoma: results of population-based study of 701 patients. Urology 2005; 66:1186.</a></li><li class="breakAll">DeKernion JB. Real numbers. In: Campbell's Urology, Walsh PC, Gittes RF, Perlmutter AD (Eds), WB Saunders, Philadelphia 1986. p.1294.</li><li><a class="nounderline abstract_t">Gibbons RP, Monte JE, Correa RJ Jr, Mason JT. Manifestations of renal cell carcinoma. Urology 1976; 8:201.</a></li><li><a class="nounderline abstract_t">PINALS RS, KRANE SM. Medical aspects of renal carcinoma. Postgrad Med J 1962; 38:507.</a></li><li><a class="nounderline abstract_t">Chisholm GD, Roy RR. The systemic effects of malignant renal tumours. Br J Urol 1971; 43:687.</a></li><li><a class="nounderline abstract_t">Laski ME, Vugrin D. Paraneoplastic syndromes in hypernephroma. Semin Nephrol 1987; 7:123.</a></li><li><a class="nounderline abstract_t">Gold PJ, Fefer A, Thompson JA. Paraneoplastic manifestations of renal cell carcinoma. Semin Urol Oncol 1996; 14:216.</a></li><li><a class="nounderline abstract_t">Cherukuri SV, Johenning PW, Ram MD. Systemic effects of hypernephroma. Urology 1977; 10:93.</a></li><li><a class="nounderline abstract_t">Sufrin G, Mirand EA, Moore RH, et al. Hormones in renal cancer. J Urol 1977; 117:433.</a></li><li><a class="nounderline abstract_t">Walsh PN, Kissane JM. Nonmetastatic hypernephroma with reversible hepatic dysfunction. Arch Intern Med 1968; 122:214.</a></li><li><a class="nounderline abstract_t">Utz DC, Warren MM, Gregg JA, et al. Reversible hepatic dysfunction associated with hypernephroma. Mayo Clin Proc 1970; 45:161.</a></li><li><a class="nounderline abstract_t">Chuang YC, Lin AT, Chen KK, et al. Paraneoplastic elevation of serum alkaline phosphatase in renal cell carcinoma: incidence and implication on prognosis. J Urol 1997; 158:1684.</a></li><li><a class="nounderline abstract_t">Boxer RJ, Waisman J, Lieber MM, et al. Non-metastatic hepatic dysfunction associated with renal carcinoma. J Urol 1978; 119:468.</a></li><li><a class="nounderline abstract_t">Chang SY, Yu DS, Sherwood ER, et al. Inhibitory effects of suramin on a human renal cell carcinoma line, causing nephrogenic hepatic dysfunction. J Urol 1992; 147:1147.</a></li><li><a class="nounderline abstract_t">Blay JY, Rossi JF, Wijdenes J, et al. Role of interleukin-6 in the paraneoplastic inflammatory syndrome associated with renal-cell carcinoma. Int J Cancer 1997; 72:424.</a></li><li><a class="nounderline abstract_t">Stadler WM, Richards JM, Vogelzang NJ. Serum interleukin-6 levels in metastatic renal cell cancer: correlation with survival but not an independent prognostic indicator. J Natl Cancer Inst 1992; 84:1835.</a></li><li><a class="nounderline abstract_t">Cranston WI, Luff RH, Owen D, Rawlins MD. Studies on the pathogenesis of fever in renal carcinoma. Clin Sci Mol Med 1973; 45:459.</a></li><li><a class="nounderline abstract_t">O'Grady AS, Morse LJ, Lee JB. Parathyroid hormone-secreting renal carcinoma associated with hypercalcemia and metabolic alkalosis. Ann Intern Med 1965; 63:858.</a></li><li><a class="nounderline abstract_t">LYTTON B, ROSOF B, EVANS JS. PARATHYROID HORMONE-LIKE ACTIVITY IN A RENAL CARCINOMA PRODUCING HYPERCALCEMIA. J Urol 1965; 93:127.</a></li><li><a class="nounderline abstract_t">GOLDBERG MF, TASHJIAN AH Jr, ORDER SE, DAMMIN GJ. RENAL ADENOCARCINOMA CONTAINING A PARATHYROID HORMONE-LIKE SUBSTANCE AND ASSOCIATED WITH MARKED HYPERCALCEMIA. Am J Med 1964; 36:805.</a></li><li><a class="nounderline abstract_t">Sandhu DP, Munson KW, Harrop JS, et al. Humoral hypercalcaemia in renal carcinoma due to parathyroid hormone related protein. Br J Urol 1993; 72:848.</a></li><li><a class="nounderline abstract_t">de la Mata J, Uy HL, Guise TA, et al. Interleukin-6 enhances hypercalcemia and bone resorption mediated by parathyroid hormone-related protein in vivo. J Clin Invest 1995; 95:2846.</a></li><li><a class="nounderline abstract_t">Weissglas M, Schamhart D, Löwik C, et al. Hypercalcemia and cosecretion of interleukin-6 and parathyroid hormone related peptide by a human renal cell carcinoma implanted into nude mice. J Urol 1995; 153:854.</a></li><li><a class="nounderline abstract_t">Brereton HD, Halushka PV, Alexander RW, et al. Indomethacin-responsive hypercalcemia in a patient with renal-cell adenocarcinoma. N Engl J Med 1974; 291:83.</a></li><li><a class="nounderline abstract_t">Robertson RP, Baylink DJ, Marini BJ, Adkison HW. Elevated prostaglandins and suppressed parathyroid hormone associated with hypercalcemia and renal cell carcinoma. J Clin Endocrinol Metab 1975; 41:164.</a></li><li><a class="nounderline abstract_t">Da Silva JL, Lacombe C, Bruneval P, et al. Tumor cells are the site of erythropoietin synthesis in human renal cancers associated with polycythemia. Blood 1990; 75:577.</a></li><li><a class="nounderline abstract_t">Iliopoulos O, Levy AP, Jiang C, et al. Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein. Proc Natl Acad Sci U S A 1996; 93:10595.</a></li><li><a class="nounderline abstract_t">Wiesener MS, Seyfarth M, Warnecke C, et al. Paraneoplastic erythrocytosis associated with an inactivating point mutation of the von Hippel-Lindau gene in a renal cell carcinoma. Blood 2002; 99:3562.</a></li><li><a class="nounderline abstract_t">Pras M, Franklin EC, Shibolet S, Frangione B. Amyloidosis associated with renal cell carcinoma of the AA type. Am J Med 1982; 73:426.</a></li><li><a class="nounderline abstract_t">Chisholm GD. Nephrogenic ridge tumors and their syndromes. Ann N Y Acad Sci 1974; 230:403.</a></li><li><a class="nounderline abstract_t">Symbas NP, Townsend MF, El-Galley R, et al. Poor prognosis associated with thrombocytosis in patients with renal cell carcinoma. BJU Int 2000; 86:203.</a></li><li><a class="nounderline abstract_t">O'Keefe SC, Marshall FF, Issa MM, et al. Thrombocytosis is associated with a significant increase in the cancer specific death rate after radical nephrectomy. J Urol 2002; 168:1378.</a></li><li><a class="nounderline abstract_t">Sidhom OA, Basalaev M, Sigal LH. Renal cell carcinoma presenting as polymyalgia rheumatica. Resolution after nephrectomy. Arch Intern Med 1993; 153:2043.</a></li><li><a class="nounderline abstract_t">Chiarello MA, Mali RD, Kang SK. Diagnostic Accuracy of MRI for Detection of Papillary Renal Cell Carcinoma: A Systematic Review and Meta-Analysis. AJR Am J Roentgenol 2018; 211:812.</a></li><li><a class="nounderline abstract_t">Kay FU, Canvasser NE, Xi Y, et al. Diagnostic Performance and Interreader Agreement of a Standardized MR Imaging Approach in the Prediction of Small Renal Mass Histology. Radiology 2018; 287:543.</a></li><li><a class="nounderline abstract_t">Johnson CD, Dunnick NR, Cohan RH, Illescas FF. Renal adenocarcinoma: CT staging of 100 tumors. AJR Am J Roentgenol 1987; 148:59.</a></li><li><a class="nounderline abstract_t">Studer UE, Scherz S, Scheidegger J, et al. Enlargement of regional lymph nodes in renal cell carcinoma is often not due to metastases. J Urol 1990; 144:243.</a></li><li><a class="nounderline abstract_t">Nayak JG, Patel P, Saarela O, et al. Pathological Upstaging of Clinical T1 to Pathological T3a Renal Cell Carcinoma: A Multi-institutional Analysis of Short-term Outcomes. Urology 2016; 94:154.</a></li><li><a class="nounderline abstract_t">Koga S, Tsuda S, Nishikido M, et al. The diagnostic value of bone scan in patients with renal cell carcinoma. J Urol 2001; 166:2126.</a></li><li><a class="nounderline abstract_t">Semelka RC, Shoenut JP, Magro CM, et al. Renal cancer staging: comparison of contrast-enhanced CT and gadolinium-enhanced fat-suppressed spin-echo and gradient-echo MR imaging. J Magn Reson Imaging 1993; 3:597.</a></li><li><a class="nounderline abstract_t">Ramdave S, Thomas GW, Berlangieri SU, et al. Clinical role of F-18 fluorodeoxyglucose positron emission tomography for detection and management of renal cell carcinoma. J Urol 2001; 166:825.</a></li><li><a class="nounderline abstract_t">Wu HC, Yen RF, Shen YY, et al. Comparing whole body 18F-2-deoxyglucose positron emission tomography and technetium-99m methylene diphosphate bone scan to detect bone metastases in patients with renal cell carcinomas - a preliminary report. J Cancer Res Clin Oncol 2002; 128:503.</a></li><li><a class="nounderline abstract_t">Goldberg MA, Mayo-Smith WW, Papanicolaou N, et al. FDG PET characterization of renal masses: preliminary experience. Clin Radiol 1997; 52:510.</a></li><li><a class="nounderline abstract_t">Dechet CB, Zincke H, Sebo TJ, et al. Prospective analysis of computerized tomography and needle biopsy with permanent sectioning to determine the nature of solid renal masses in adults. J Urol 2003; 169:71.</a></li><li><a class="nounderline abstract_t">Bosniak MA, Birnbaum BA, Krinsky GA, Waisman J. Small renal parenchymal neoplasms: further observations on growth. Radiology 1995; 197:589.</a></li><li><a class="nounderline abstract_t">Sánchez-Ortiz RF, Madsen LT, Bermejo CE, et al. A renal mass in the setting of a nonrenal malignancy: When is a renal tumor biopsy appropriate? Cancer 2004; 101:2195.</a></li><li class="breakAll">Rini BI, McKiernan JM, Chang SS, et al. Kidney. In: AJCC Cancer Staging Manual, 8th, Amin MB (Ed), Springer, New York 2017. p.739.</li><li><a class="nounderline abstract_t">Vogelzang NJ, Stadler WM. Kidney cancer. Lancet 1998; 352:1691.</a></li></ol></div><div id="topicVersionRevision">Topic 2983 Version 34.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="javascript:alert('بدون لینک');" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Garnick MB. Primary neoplasms of the kidney. In: Therapy in Nephrology and Hypertension: A Companion to Brenner and Rector's the Kidney, Brady HR, Wilcox CS (Eds), WB Saunders, Philadelphia 1998.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5125665" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Diagnosis and management of renal cell carcinoma. A clinical and pathologic study of 309 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28642870" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Imaging and Management of Incidental Renal Lesions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16360438" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Effect of incidental detection for survival of patients with renal cell carcinoma: results of population-based study of 701 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16360438" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Effect of incidental detection for survival of patients with renal cell carcinoma: results of population-based study of 701 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/788291" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Manifestations of renal cell carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14486698" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Medical aspects of renal carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5159572" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : The systemic effects of malignant renal tumours.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3306861" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Paraneoplastic syndromes in hypernephroma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8946620" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Paraneoplastic manifestations of renal cell carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/898463" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Systemic effects of hypernephroma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/850315" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Hormones in renal cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5671101" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Nonmetastatic hypernephroma with reversible hepatic dysfunction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5435856" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Reversible hepatic dysfunction associated with hypernephroma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9334578" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Paraneoplastic elevation of serum alkaline phosphatase in renal cell carcinoma: incidence and implication on prognosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/650745" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Non-metastatic hepatic dysfunction associated with renal carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1552613" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Inhibitory effects of suramin on a human renal cell carcinoma line, causing nephrogenic hepatic dysfunction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9247285" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Role of interleukin-6 in the paraneoplastic inflammatory syndrome associated with renal-cell carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1433373" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Serum interleukin-6 levels in metastatic renal cell cancer: correlation with survival but not an independent prognostic indicator.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4751965" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Studies on the pathogenesis of fever in renal carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5848632" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Parathyroid hormone-secreting renal carcinoma associated with hypercalcemia and metabolic alkalosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14260201" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : PARATHYROID HORMONE-LIKE ACTIVITY IN A RENAL CARCINOMA PRODUCING HYPERCALCEMIA.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14141455" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : RENAL ADENOCARCINOMA CONTAINING A PARATHYROID HORMONE-LIKE SUBSTANCE AND ASSOCIATED WITH MARKED HYPERCALCEMIA.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8306145" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Humoral hypercalcaemia in renal carcinoma due to parathyroid hormone related protein.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7769125" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Interleukin-6 enhances hypercalcemia and bone resorption mediated by parathyroid hormone-related protein in vivo.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7861550" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Hypercalcemia and cosecretion of interleukin-6 and parathyroid hormone related peptide by a human renal cell carcinoma implanted into nude mice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4835887" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Indomethacin-responsive hypercalcemia in a patient with renal-cell adenocarcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1150858" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Elevated prostaglandins and suppressed parathyroid hormone associated with hypercalcemia and renal cell carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2297568" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Tumor cells are the site of erythropoietin synthesis in human renal cancers associated with polycythemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8855223" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11986208" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Paraneoplastic erythrocytosis associated with an inactivating point mutation of the von Hippel-Lindau gene in a renal cell carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7124769" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Amyloidosis associated with renal cell carcinoma of the AA type.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4595951" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Nephrogenic ridge tumors and their syndromes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10930915" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Poor prognosis associated with thrombocytosis in patients with renal cell carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12352397" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Thrombocytosis is associated with a significant increase in the cancer specific death rate after radical nephrectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8357289" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Renal cell carcinoma presenting as polymyalgia rheumatica. Resolution after nephrectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30063398" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Diagnostic Accuracy of MRI for Detection of Papillary Renal Cell Carcinoma: A Systematic Review and Meta-Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29390196" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Diagnostic Performance and Interreader Agreement of a Standardized MR Imaging Approach in the Prediction of Small Renal Mass Histology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3491524" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Renal adenocarcinoma: CT staging of 100 tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2374186" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Enlargement of regional lymph nodes in renal cell carcinoma is often not due to metastases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27041471" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Pathological Upstaging of Clinical T1 to Pathological T3a Renal Cell Carcinoma: A Multi-institutional Analysis of Short-term Outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11696720" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : The diagnostic value of bone scan in patients with renal cell carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8347952" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Renal cancer staging: comparison of contrast-enhanced CT and gadolinium-enhanced fat-suppressed spin-echo and gradient-echo MR imaging.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11490227" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Clinical role of F-18 fluorodeoxyglucose positron emission tomography for detection and management of renal cell carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12242515" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Comparing whole body 18F-2-deoxyglucose positron emission tomography and technetium-99m methylene diphosphate bone scan to detect bone metastases in patients with renal cell carcinomas - a preliminary report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9240703" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : FDG PET characterization of renal masses: preliminary experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12478106" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Prospective analysis of computerized tomography and needle biopsy with permanent sectioning to determine the nature of solid renal masses in adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7480724" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Small renal parenchymal neoplasms: further observations on growth.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15470708" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : A renal mass in the setting of a nonrenal malignancy: When is a renal tumor biopsy appropriate?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15470708" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : A renal mass in the setting of a nonrenal malignancy: When is a renal tumor biopsy appropriate?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9853456" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Kidney cancer.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
